Literature DB >> 12672259

Treatment of agitation in bipolar disorder across the life cycle.

Benjamin S Alderfer1, Michael H Allen.   

Abstract

Agitation is a common and difficult problem in psychiatric patients; patients with bipolar disorder constitute a substantial proportion of the agitated psychiatric population. Agitation is often seen in bipolar patients during acute manic states, when increased energy levels and reduced need for sleep lead patients to collide with the limits of others. Agitation also occurs during mixed and depressive states, which are characterized by fluctuating energy levels and periods of irritability. Although the prevalence of agitation is similar in men and women, its presentation often differs between the sexes. In addition, the presentations of bipolar disorder in children and in geriatric patients, and thus the manifestations of illness-related agitation, differ both from each other and from that of younger adults. Intensive treatment is required to manage agitated bipolar patients in a manner that rapidly decreases their suffering and maintains their safety and the safety of those around them. Considerations of speed and predictability tend to drive decisions in this setting more than concerns about tolerability. Oral or parenteral benzodiazepines, alone or in combination with an antipsychotic, are recommended as first-line treatment for the termination of behavioral emergencies in mania. Once behavioral control is restored, evidence suggests the combination of orally loaded divalproex sodium with an atypical antipsychotic is associated with more rapid improvement. Medication treatment of children and of geriatric patients must take into account developmental influences on the presentation of bipolar disorder in these different patient groups.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12672259

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  13 in total

1.  Psychoradiologic abnormalities of white matter in patients with bipolar disorder: diffusion tensor imaging studies using tract-based spatial statistics

Authors:  Cheng Yang; Lei Li; Xinyu Hu; Qiang Luo; Weihong Kuang; Su Lui; Xiaoqi Huang; Jing Dai; Manxi He; Graham J. Kemp; John A Sweeney; Qiyong Gong
Journal:  J Psychiatry Neurosci       Date:  2019-01-01       Impact factor: 6.186

2.  Symptomatic response to divalproex in subtypes of conduct disorder.

Authors:  Ranjit Padhy; Kirti Saxena; Lisa Remsing; Julia Huemer; Belinda Plattner; Hans Steiner
Journal:  Child Psychiatry Hum Dev       Date:  2011-10

3.  Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia.

Authors:  David W Boulton; Georgia Kollia; Suresh Mallikaarjun; Bernard Komoroski; Anjali Sharma; Lawrence J Kovalick; Richard A Reeves
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 4.  Prepubertal bipolar disorder: proper diagnosis should lead to better treatment response.

Authors:  Edith M Jolin; Elizabeth B Weller; Ronald A Weller
Journal:  Curr Psychiatry Rep       Date:  2005-04       Impact factor: 8.081

5.  Revisiting loxapine: a systematic review.

Authors:  Dina Popovic; Philippe Nuss; Eduard Vieta
Journal:  Ann Gen Psychiatry       Date:  2015-04-01       Impact factor: 3.455

6.  Multiple dose pharmacokinetics of inhaled loxapine in subjects on chronic, stable antipsychotic regimens.

Authors:  Daniel A Spyker; Robert A Riesenberg; James V Cassella
Journal:  J Clin Pharmacol       Date:  2015-05-06       Impact factor: 3.126

7.  Response to inhaled loxapine in patients with schizophrenia or bipolar I disorder: PANSS-EC responder analyses.

Authors:  Scott Zeller; Leslie Zun; James V Cassella; Daniel A Spyker; Paul P Yeung
Journal:  BJPsych Open       Date:  2017-11-10

8.  The use of atypical antipsychotics beyond psychoses: efficacy of quetiapine in bipolar disorder.

Authors:  Emanuela Mundo; Elisabetta Cattaneo; Silvia Zanoni; A Carlo Altamura
Journal:  Neuropsychiatr Dis Treat       Date:  2006-06       Impact factor: 2.570

9.  Inhaled loxapine and intramuscular lorazepam in healthy volunteers: a randomized placebo-controlled drug-drug interaction study.

Authors:  Daniel A Spyker; James V Cassella; Randall R Stoltz; Paul P Yeung
Journal:  Pharmacol Res Perspect       Date:  2015-12-17

10.  The effect of the medicine administration route on health-related quality of life: Results from a time trade-off survey in patients with bipolar disorder or schizophrenia in 2 Nordic countries.

Authors:  Tine Rikke Jørgensen; Charlotte Emborg; Karianne Dahlen; Mette Bøgelund; Andreas Carlborg
Journal:  BMC Psychiatry       Date:  2016-07-16       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.